Health
Health New drug could mean a longer, healthier life
If trials succeed, senolytics may reverse ageing and reduce the risk of chronic diseases
Ageing and death have for long held people captive in fear. This fear has raked in thousands for plastic surgeons and companies lauding products and processes that will prolong your life or, at the very least, your health. It is out of this fear that the company Ambrosia, a startup that offered transfusions of human plasma harvested from young donors from the age of 16 and 25 years, to clients 30 years or older, managed to stay in business for a year-and-a-half before closing its doors. Its claims that the process could improve health ailments and extend a person’s life were controversial and unproven. Earlier in 2019, the startup closed its doors after the American Food and Drug Administration (FDA) issued a warning to potential customers, citing public health concerns and informing them that these treatments had not undergone FDA testing and should be assumed to be unsafe and ineffective. The cohorts who were willing to pay more than R113,000 for one litre of young blood will rejo...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.